Evaluation of tri-combinant vaccine for feline herpesvirus, calicivirus and panleukopenia virus infections in Japanese native cats.
Tri-combinant vaccine consisting of attenuated feline herpesvirus (FHV) and feline calicivirus (FCV) and inactivated feline panleukopenia virus (FPLV), were evaluated for safety and efficacy, using Japanese native cats and the viral strains isolated in Japan. Thirty-eight 9- to 12-week-old kittens were inoculated intramuscularly and subcutaneously with the vaccine. Consequently, no adverse reaction was found, and protective efficacy was confirmed by challenge tests with the virulent strains of each virus. Serum-neutralizing antibodies against FCV and FPLV were maintained for at least one year after vaccination, whereas antibody against FHV disappeared in two cases at 24 weeks after vaccination. Application of this vaccine seemed effective for control of feline viral disease in cats for experimental use.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002139:Caliciviridae / Q000276:immunology*; D002371:Cat Diseases / Q000276:immunology*; D002415:Cats / Q000276:immunology*; D005069:Evaluation Studies as Topic; D005254:Feline Panleukopenia / Q000276:immunology*; D028301:Feline Panleukopenia Virus / Q000276:immunology*; D006564:Herpesviridae / Q000276:immunology*; D006566:Herpesviridae Infections / Q000662:veterinary*; D007111:Immunity, Cellular; D010321:Parvoviridae / Q000276:immunology*; D010850:Picornaviridae Infections / Q000662:veterinary*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines